Relay Therapeutics, Inc. (RLAY) Balance Sheet

The sequential jump in total assets from $699.6M to $967.5M in 2026Q2, alongside a $247.8M increase in equity, suggests a significant capital infusion, likely from an equity offering. However, retained earnings fell from -$2.1B to -$2.2B, reflecting continued operational losses. This pattern indicates that while the balance sheet is temporarily fortified, the underlying business is still consuming cash at a rapid pace, and the trajectory depends on the success of pipeline milestones to reverse the burn.

The consistent reduction in total debt, now just 3.2% of total assets, suggests that the company is not reliant on borrowings to fund operations. The low D/E ratio, comparable to peers like Kymera and Arvinas, implies that debt service is not a constraint. This deleveraging trend, combined with a strong cash position, suggests that the company's balance sheet is positioned to support ongoing R&D investment without near-term refinancing risk.

The steady decline in net PP&E, now just 3.9% of total assets, indicates minimal capital intensity, consistent with a research-driven biotech. The elimination of goodwill, which was $2.3M in early 2025, suggests that any prior acquisitions have been fully impaired or written off, reducing the risk of future goodwill impairment charges. The asset mix is dominated by cash and investments, reflecting a business model that relies on intellectual property and human capital rather than physical assets.

The substantial equity increase in 2026Q2, despite a widening accumulated deficit, points to a significant equity issuance. This suggests that the company is proactively raising capital to extend its cash runway, likely ahead of clinical data readouts. However, the reliance on external funding rather than organic earnings means that equity quality is dependent on the market's willingness to fund future rounds, which could be a risk if sentiment shifts.

The current ratio of 18.27 is exceptionally high, indicating that current assets vastly exceed current liabilities, providing a strong buffer against short-term obligations. However, the absolute cash balance of $121.2M is modest relative to the company's burn rate, which has been accelerating. Even with the recent capital raise, the company may need to secure additional financing within the next few quarters to sustain operations, highlighting the importance of pipeline progress in reducing cash consumption.